Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study.

ABSTRACT:

Background

Sensor-augmented pump (SAP) therapy can improve glycemic control, compared with multiple daily insulin injections or with insulin pump therapy alone, without increasing the risk of hypoglycemia.

Subjects and methods

A 12-month observational study in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII), upon the introduction of continuous glucose monitoring (CGM), was conducted in 15 countries (in Europe and in Israel) to document the real-life use of SAP and assess which variables are associated with improvement in type 1 diabetes management.

Results

Data from 263 patients (38% male; mean age, 28.0 ± 15.7 years [range, 1-69 years]; body mass index, 23.3 ± 4.9 kg/m(2); diabetes duration, 13.9 ± 10.7 years; CSII duration,

SUBMITTER: Norgaard K 

PROVIDER: S-EPMC3696941 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature